These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 11751379)
1. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379 [TBL] [Abstract][Full Text] [Related]
2. Role of HPC2/ELAC2 in hereditary prostate cancer. Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646 [TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Suarez BK; Gerhard DS; Lin J; Haberer B; Nguyen L; Kesterson NK; Catalona WJ Cancer Res; 2001 Jul; 61(13):4982-4. PubMed ID: 11431329 [TBL] [Abstract][Full Text] [Related]
6. A region close to Tp53 shows LOH in familial breast cancer. Luo L; Chen J; Du Q; Dumanski J; Blennow E; Kockum I; Luthman H; Lindblom A Int J Mol Med; 2002 Apr; 9(4):405-9. PubMed ID: 11891537 [TBL] [Abstract][Full Text] [Related]
7. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Yokomizo A; Koga H; Kinukawa N; Tsukamoto T; Hirao Y; Akaza H; Mori M; Naito S Prostate; 2004 Nov; 61(3):248-52. PubMed ID: 15368467 [TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Hu CK; McCall S; Madden J; Huang H; Clough R; Jirtle RL; Anscher MS Prostate Cancer Prostatic Dis; 2006; 9(1):62-7. PubMed ID: 16304558 [TBL] [Abstract][Full Text] [Related]
9. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322 [TBL] [Abstract][Full Text] [Related]
10. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population. Suzuki K; Ohtake N; Nakata S; Takei T; Matsui H; Ono Y; Nakazato H; Hasumi M; Koike H; Ito K; Fukabori Y; Kurokawa K; Yamanaka H Anticancer Res; 2002; 22(6B):3507-11. PubMed ID: 12552947 [TBL] [Abstract][Full Text] [Related]
11. Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series. Fujiwara H; Emi M; Nagai H; Nishimura T; Konishi N; Kubota Y; Ichikawa T; Takahashi S; Shuin T; Habuchi T; Ogawa O; Inoue K; Skolnick MH; Swensen J; Camp NJ; Tavtigian SV J Hum Genet; 2002; 47(12):641-8. PubMed ID: 12522685 [TBL] [Abstract][Full Text] [Related]
12. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138 [TBL] [Abstract][Full Text] [Related]
13. Distinct regions of allelic loss on 13q in prostate cancer. Cooney KA; Wetzel JC; Merajver SD; Macoska JA; Singleton TP; Wojno KJ Cancer Res; 1996 Mar; 56(5):1142-5. PubMed ID: 8640774 [TBL] [Abstract][Full Text] [Related]
15. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Yin Z; Spitz MR; Babaian RJ; Strom SS; Troncoso P; Kagan J Oncogene; 1999 Dec; 18(52):7576-83. PubMed ID: 10602517 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448 [TBL] [Abstract][Full Text] [Related]
17. Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Cunningham JM; McDonnell SK; Marks A; Hebbring S; Anderson SA; Peterson BJ; Slager S; French A; Blute ML; Schaid DJ; Thibodeau SN; Prostate; 2003 Dec; 57(4):335-46. PubMed ID: 14601030 [TBL] [Abstract][Full Text] [Related]
18. Involvement of the RNAse L gene in prostate cancer. Kieffer N; Schmitz M; Scheiden R; Nathan M; Faber JC Bull Soc Sci Med Grand Duche Luxemb; 2006; (1):21-8. PubMed ID: 16869093 [TBL] [Abstract][Full Text] [Related]
19. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798 [TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer. Ueda T; Komiya A; Suzuki H; Shimbo M; Sakamoto S; Imamoto T; Akakura K; Shiraishi T; Ichikawa T Prostate; 2005 Aug; 64(3):265-71. PubMed ID: 15717310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]